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Personalized medicine aims to tailor diagnosis and treatment based on an individual’s personal
genetic make-up and other predictive biomarkers—rather than a one-size fits all approach.
African-Americans comprise 13.2% of the U.S. population (U.S. Census Bureau, 2014) and
minorities (consisting of all but non-Hispanic Caucasian), now 37% of the U.S. population, are
projected to reach closer to 57% in 2060 (U.S. Census Bureau, 2012). Indeed in coming decades
minority population, including African-Americans, may exceed the Caucasian population in the
U.S.
Dementia, especially Alzheimer’s disease (AD), has emerged as one of the biggest threats to
public health and personal wellbeing among older adults. Epidemiological studies, by nature
of their community sampling, have been able to study risk for AD in racially representative
populations. In such studies, older African-Americans have been reported as beingmore likely than
older Caucasians to develop AD and other dementias (Gurland et al., 1999; Dilworth-Anderson
et al., 2008; Potter et al., 2009; Barnes and Bennett, 2014; Alzheimer’s Association, 2015). Potter
et al. (2009), Gurland et al. (1999), and Barnes and Bennett (2014) report that prevalence of
cognitive impairment or AD among African-Americans may be two or three times higher than
in Caucasians. By 2050, according to The Alzheimer’s Association annual report from 2010,
proportion of racial minorities with AD will increase from 20 to 42%, with African-Americans
increasing from 9 to 12% (Alzheimer’s Association, 2010). A more recent 2015 report suggests
that 16% of African-Americans were diagnosed with AD or other dementias compared to 8% of
Caucasians (Alzheimer’s Association, 2015).
CURRENT STATUS
However, despite community studies suggesting they may be more susceptible to AD, African-
Americans have been under-included in many prominent U.S. AD biomarker and clinical trials.
In fact, barring a handful of studies in Asia and Africa, most of what we know about AD
biomarkers and pathological changes comes almost exclusively from research studies of Caucasians
(Brickman et al., 2008; Alzheimer’s Association, 2010). Clinical trials and biomarker studies rely
on convenience samples mostly recruited via advertisement. Further, we had great difficulty
ascertaining the percentage of African-Americans in various trials since journals do not require
trials to report a racial breakdown and many studies simply report percentage of Caucasians.
Table 1 lists 10 major federally-funded biomarker studies conducted in the U.S. to illustrate that
over half of these studies did not recruit adequate (approaching the USA national figure of 13%)
numbers of African-American study subjects (for reasons specific to each study). For example,
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has made major contributions to our
understanding of the pathological cascade and timeline of AD changes. Yet, ADNI-1 did not have
sufficient number of African-Americans (<5%) to reliably examine whether African-Americans
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TABLE 1 | Selected federally funded Alzheimer’s biomarker and clinical research trials.
Study Source % AA (%) Purpose of study
ADNI-1 Weiner et al., 2013; Alzheimer’s Disease
Neuroimaging Initiative, 2015
4.8 To develop CSF, blood, and imaging biomarkers as outcome
measures using a national cohort of CN, MCI, AD subjects
ADNIGO 3.1 To examine biomarkers in earlier stage of AD progression by
including early MCI
ADNI-2 4.3 To develop CSF, blood, and imaging biomarkers as predictors of
cognitive decline and outcome measures
DoD-ADNI Sibener et al., 2014; Weiner, 2014 7.1 To use imaging and other biomarkers to establish the biological
connections between TBI, PTSD and AD in Vietnam War veterans.
Enrolment is still ongoing.
WHI-Cog Goveas et al., 2011 7.0 To explore the causal relationship between depressive symptoms
in postmenopausal women and MCI/dementia
SPRINT-MIND Ambrosius et al., 2014 29.9* To use cognitive assessments and structural brain imaging to
measure the incidence of all-cause dementia in a subset of
SPRINT participants
Cache County Study on
Memory in Aging
Tschanz et al., 2013 <1** To examine the role of genetic, psychosocial, and environmental
risk factors for AD on its progression and late-life cognitive decline
in a 12-year longitudinal study
Rush Memory and Aging
Project
Bennett et al., 2012 <12.2** To use CSF, blood, and postmortem brain neuropathologic
evaluation to explore the relationship between age-related
cognitive and motor decline and the risk of AD
WHICAP Cosentino et al., 2010 31 To investigate the association between plasma amyloid beta and
cognitive change and its implication for risk of AD
Brickman et al., 2008 34.6 To use imaging biomarkers to compare brain region volumes
among multiethnic cognitively normal elderly
Mayo Clinic Study of Aging Roberts et al., 2008 <7.1** To establish a population-based cohort for studying the
prevalence, incidence, and risk factors of MCI and dementia
%AA, percentage of African-American participants in each study; ADNI, Alzheimer’s Disease Neuroimaging Initiative; GO, Grand Opportunities; CN, cognitively normal; MCI, mild cognitive
impairment; AD, Alzheimer’s disease; DoD, Department of Defense; TBI, Traumatic Brain Injury; PTSD, Post-traumatic Stress Disorder; WHI, Women’s Health Initiative; SPRINT, Systolic
Blood Pressure Intervention Trial; WHICAP, Washington Heights and Inwood Columbia Aging Project.
*The percentage of African-Americans refer to the sample demographics of SPRINT, the parent study of SPRINT-MIND.
**The percentage of African-Americans was not mentioned in the studies, and thus was deduced from the percentage of Caucasians; % Caucasian in Cache County Study on Memory
and Aging was 99%, Rush Memory and Aging Project was 87.8%, and Mayo Clinic Study of Aging was 92.9%.
differed from Caucasians. Likewise, with the exception of a
multicenter trial of donepezil conducted exclusively in African-
Americans (Griffith et al., 2006), almost all U.S. therapeutic
information we have on what drugs work or do not work for AD
(based on hundreds of industry sponsored AD clinical trials over
four decades) is primarily derived from Caucasians.
Two major studies, SPRINT-MIND and the Washington
Heights and Inwood Columbia Aging Project (WHICAP) did
enroll sufficient numbers of African-Americans (Brickman et al.,
2008; Cosentino et al., 2010; Ambrosius et al., 2014). Another
study that had a substantive proportion of African-American
participants was that conducted by Cosentino et al. (2010) as a
part of WHICAP. Their goal was to associate plasma amyloid
beta level with cognitive change indicative of AD progression,
and in doing so, they recruited same number of Caucasian
and African-American participants, each constituting 31% of
the entire sample. They concluded that higher plasma amyloid
beta level correlated with faster cognitive decline, noted in AD
onset. As stated previously, to our knowledge, there has been
only one US multicenter therapeutic drug trial done focused
solely on African Americans with AD (Griffith et al., 2006).
This 12-week multicenter trial of donepezil in 126 African
Americans concluded it was safe and effective in mild-moderate
AD (Griffith et al., 2006). However, the open label design (without
placebo control) and the fact that ∼51% of the subjects suffered
adverse effects including diarrhea, hypertension and urinary tract
infections, leaves open the question of whether the drug was truly
effective.
Thus, while much progress has been made in AD research, it
is clear that much of our knowledge about AD pathogenesis still
comes from studies of Caucasians. One obstacle for recruiting
African-American subjects is distrust of research studies led by
hospitals, universities, and clinics due to historical mistreatments
(Diaz et al., 2008; Ballard et al., 2010; Byrd et al., 2011; Lang
et al., 2013). In this regards, it is encouraging to note that a recent
survey of 5979 people in five US cities (Pease, 2013) found that
91% of African-Americans indicated interest in participating in
research—suggesting that the onus is now on researchers to reach
out to them and to not abuse their trust.
RECOMMENDATIONS FOR FUTURE
While punitive approaches to enhance recruitment (e.g., tying
grant payments to minority recruitment success or imposition of
institutional penalties for failure to recruit sufficient minorities)
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may force change, we believe they are not ideal. We have some
recommendations for enhancing African-American recruitment:
(1) building long-standing partnerships with local African-
American community organizations such as churches and
initiations of forums, retreats, and other social events for greater
approachability and getting to know the subjects on a more
personal level (Ballard et al., 2010); (2) including a substantial
budget for recruiting minorities in every major trial; (3) creating
community based multiethnic registries (e.g., Brain Health
Registry; Bryan ADRC Registry); (4) including a well powered
hypothesis aimed at African Americans (or other major minority
groups) in every major federally funded AD clinical trial; (5)
explicit reporting in study reports and journal publications of
percentage of African-Americans and other races, and whether
race influenced any outcomes; (6) specific funding to conduct
trials aimed at under-recruited minorities.
It is our hope that including a greater proportion of
African-Americans in AD clinical trials will allow researchers to
produce more generalizable results and a better understanding
of race and ethnicity-specific differences in AD pathophysiology.
This awareness and knowledge would help clinicians improve
therapeutic target responses in patients and optimize the delivery
of personalized care for more individuals with AD. Similar efforts
aimed at Asians and Hispanics are already underway in other
countries, and together these studies will help us paint a fuller
picture of AD.
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